^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    isunakinra (EBI-005)

    i
    Other names: EBI-005
    Associations

    News

    Trials
    Company:
    Buzzard Pharma
    Drug class:
    IL-1R1 inhibitor
    Associations

    News

    Trials
    1year
    Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) (clinicaltrials.gov)
    P2, N=20, Recruiting, Buzzard Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • isunakinra (EBI-005)
    over1year
    Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Buzzard Pharmaceuticals
    New P2 trial
    |
    Keytruda (pembrolizumab) • isunakinra (EBI-005)
    over1year
    Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=15, Completed, Buzzard Pharmaceuticals | Recruiting --> Completed | N=25 --> 15 | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Jul 2024 --> Dec 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    isunakinra (EBI-005)
    3years
    Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Buzzard Pharmaceuticals | Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jan 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    isunakinra (EBI-005)
    over4years
    [VIRTUAL] LSC - 2021 - Preclinical evaluation of IL-1ß inhibition against KRAS-mutant lung adenocarcinoma (ERS 2021)
    To test this, we used a novel, specific inhibitor of IL-1ß signaling called isunakinra and cancer cell lines stably expressing a NF-?B reporter bioluminescent plasmid, in both in vitro and in vivo assays...Similar results were also obtained using the flank tumor model, in which the drug was effective in reducing primary tumor volume and occurrence of pulmonary metastases. Collectively, our results show that IL-1ß inhibition may constitute a novel therapeutic strategy to target KRAS-mutant tumors.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    isunakinra (EBI-005)
    over4years
    Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Buzzard Pharmaceuticals | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    isunakinra (EBI-005)
    over5years
    Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Buzzard Pharmaceuticals | Not yet recruiting --> Recruiting | Initiation date: Jan 2020 --> Sep 2020
    Clinical • Enrollment open • Trial initiation date • Combination therapy
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    isunakinra (EBI-005)